The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid

Summary

This is an open-label, pilot study evaluating the efficacy of tildrakizumab on the treatment of bullous pemphigoid (BP) in eligible patients (see detailed study protocol). Three total doses of tildrakizumab 100mg will be administered at Weeks 0, 4, 16 a total of 16 weeks of treatment by the study staff to patients with bullous pemphigoid. The patients will be followed for a total of 24 weeks.

Timeline

Start

2020-09-01

Primary completion

2022-12-01

Completion

2023-05-01

Drugs

Indications